久久精品国产99国产精品亚洲,久久亚洲一区二区三区四区五区高,久久久一区二区三区视频,午夜精品一码二码三码,亚洲欧美另类在线视频,一区二区电影在线,国产香蕉97

ABOUT

 

Xiamen OneClone Biotech Inc. was established in 2011 and is located in the National Innovation and Entrepreneurship Park of Xiamen Torch High-Tech Zone. The company is a high-tech enterprise founded by overseas returnees and recognized as a "Double Hundred Talent" enterprise by the Xiamen Municipal Government. The company has introduced leading high-tech talents from Singapore and the United States, specializing in the R&D, production, and sales of bioactive raw materials for diagnostic reagents.

The company is primarily dedicated to the R&D and production of antigens and antibodies for immunodiagnostics, including(but not limited to):

· Respiratory Infectious Diseases: eg.Natural/recombinant Mycoplasma pneumoniae, Chlamydia pneumoniae, Respiratory syncytial virus, Adenovirus, Influenza A/B, Parainfluenza virus, Human metapneumovirus, Rhinovirus, and Bordetella pertussis.

· Hand, Foot, and Mouth Disease

· Hepatitis Virus

· prenatal and perinatal screening 

· Mycobacterium tuberculosis

· Helicobacter pylori

· Immunization Efficacy Monitoring

· Animal/Pet Infectious Diseases

· Autoimmune Diseases

The products are characterized by high specificity, high sensitivity, and excellent stability, with quality meeting or exceeding comparable domestic and international products, and have gained broad recognition among diagnostic-reagent manufacturers.

With a strong focus on independent R&D and collaboration with research institutions such as Xiamen University, the company continuously develops new technologies and products. As a professional enterprise dedicated to the R&D and production of bioactive raw materials for diagnostic reagents, Xiamen OneClone Biotechnology is committed to advancing into the future, striving to provide high-quality bioactive materials for diagnostic reagent manufacturers and research institutions, fostering mutual success.

 

d0570db40ce91535cd0fa939da0525e.jpg


MORE+

PRODUCTS

MORE+

NEWS

MORE+
展開